Price
$3.11
Increased by +0.32%
Dollar volume (20D)
897.62 K
ADR%
11.60
Shares float
11.36 M
Shares short
507.13 K [4.46%]
Shares outstanding
16.98 M
Market cap
52.64 M
Beta
0.19
Price/earnings
N/A
20D range
1.42 3.12
50D range
0.81 3.12
200D range
0.40 3.12

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.

ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.

The company is headquartered in Fremont, California.

ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Apr 15, 25 0.02
Increased by +105.10%
-
Nov 13, 24 -0.01
Increased by +98.17%
-
Aug 14, 24 -0.09
Increased by +86.93%
-
May 17, 24 -0.40
Decreased by -573.33%
-
Mar 13, 24 -0.39
Decreased by -161.20%
-
Nov 15, 23 -0.82
Decreased by -643.73%
-0.04
Decreased by -1.95 K%
Aug 14, 23 -0.68
Decreased by -1.04 K%
-0.06
Decreased by -1.04 K%
May 15, 23 -0.06
Increased by +70.00%
-0.05
Decreased by -20.00%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 1.97 K
Increased by +63.07%
-842.00 K
Increased by +78.59%
Decreased by -42.85 K%
Increased by +86.87%
Dec 31, 24 1.97 K
Decreased by -9.19%
229.30 K
Increased by +107.37%
Increased by +11.66 K%
Increased by +108.12%
Sep 30, 24 389.28 K
Increased by +2.35 K%
-186.56 K
Increased by +94.38%
Decreased by -47.93%
Increased by +99.77%
Jun 30, 24 117.14 K
Increased by +1.82 K%
-1.01 M
Increased by +55.26%
Decreased by -864.76%
Increased by +97.67%
Mar 31, 24 1.21 K
Decreased by -99.06%
-3.93 M
Decreased by -115.66%
Decreased by -326.39 K%
Decreased by -22.86 K%
Dec 31, 23 2.17 K
Decreased by -99.63%
-3.11 M
Increased by +36.04%
Decreased by -143.70 K%
Decreased by -17.30 K%
Sep 30, 23 15.88 K
Decreased by -62.42%
-3.32 M
Increased by +10.44%
Decreased by -20.89 K%
Decreased by -138.32%
Jun 30, 23 6.11 K
Decreased by -98.05%
-2.26 M
Decreased by -21.79%
Decreased by -37.06 K%
Decreased by -6.14 K%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY